首页> 外文学位 >Understanding Carbohydrate Recognition by Antiviral Lectins: Applying Computational Methods to Protein--Carbohydrate Complexes.
【24h】

Understanding Carbohydrate Recognition by Antiviral Lectins: Applying Computational Methods to Protein--Carbohydrate Complexes.

机译:了解抗病毒凝集素对碳水化合物的识别:将计算方法应用于蛋白质-碳水化合物复合物。

获取原文
获取原文并翻译 | 示例

摘要

Human immunodeficiency virus (HIV) infection of T-cells begins when the viral envelope glycoprotein, gp120, binds to CD4 receptors on the target cell surface. Over the past several years, proteins isolated from various prokaryotes have been shown to inhibit HIV cell entry by binding to gp120 and thus blocking the association with CD4. Lectins that bind to high-mannose oligosaccharides on gp120 are an attractive class of antiviral agents. While several of these have been quite well characterized both structurally and biochemically, there remain many open questions regarding their mechanism of inhibition. Among the best studied is cyanovirin-N (CVN), which is currently under clinical study for use as a topical prophylactic. Large-scale molecular dynamics simulations have identified important structural features of this system that are difficult to resolve experimentally, and binding free energies of a diverse set of oligosaccharide targets computed from these structural ensembles give remarkable agreement with experiment. Detailed decompositions of the binding free energies on a residue-by-residue basis have additionally identified several key interactions that define broad affinity for alpha-(1,2)-dimannose-containing sugars, as well as a number of determinants of specificity. These studies provide a deeper understanding of the mechanism of inhibitory activity. In addition, this work has provided a foundation for methodological improvements that allow us to more accurately capture the energetics of carbohydrate binding.
机译:当病毒包膜糖蛋白gp120与靶细胞表面的CD4受体结合时,T细胞就会被人类免疫缺陷病毒(HIV)感染。在过去的几年中,从各种原核生物中分离出的蛋白质已显示出通过与gp120结合从而抑制与CD4的结合来抑制HIV细胞进入。与gp120上的高甘露糖寡糖结合的凝集素是一类有吸引力的抗病毒药物。尽管其中一些已经在结构和生化上得到了很好的表征,但是关于其抑制机理仍然存在许多悬而未决的问题。在研究最好的药物中,氰维霉素-N(CVN)目前正在临床研究中,以用作局部预防剂。大规模的分子动力学模拟已经确定了该系统的重要结构特征,这些重要的结构特征很难通过实验解决,并且从这些结构集合计算出的各种低聚糖靶标的结合自由能与实验具有显着的一致性。在每个残基的基础上对结合自由能的详细分解还确定了几个关键相互作用,这些相互作用定义了对含α-(1,2)-二甘露糖的糖的广泛亲和力,以及许多特异性决定因素。这些研究为抑制活性的机制提供了更深入的了解。此外,这项工作为方法改进提供了基础,使我们能够更准确地捕获碳水化合物结合的能量。

著录项

  • 作者

    Fujimoto, Yukiji Karen.;

  • 作者单位

    State University of New York at Stony Brook.;

  • 授予单位 State University of New York at Stony Brook.;
  • 学科 Chemistry Biochemistry.;Biophysics General.
  • 学位 Ph.D.
  • 年度 2012
  • 页码 122 p.
  • 总页数 122
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号